Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA435702
Max Phase: Preclinical
Molecular Formula: C26H28N4O
Molecular Weight: 412.54
Molecule Type: Small molecule
Associated Items:
ID: ALA435702
Max Phase: Preclinical
Molecular Formula: C26H28N4O
Molecular Weight: 412.54
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1cc(-c2ccn3c(-c4ccccc4)cnc3c2)ccn1CCCN1CCCCC1
Standard InChI: InChI=1S/C26H28N4O/c31-26-19-23(10-16-29(26)15-7-14-28-12-5-2-6-13-28)22-11-17-30-24(20-27-25(30)18-22)21-8-3-1-4-9-21/h1,3-4,8-11,16-20H,2,5-7,12-15H2
Standard InChI Key: JPWAQYSLKMIFOO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 412.54 | Molecular Weight (Monoisotopic): 412.2263 | AlogP: 4.71 | #Rotatable Bonds: 6 |
Polar Surface Area: 42.54 | Molecular Species: BASE | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.18 | CX LogP: 3.04 | CX LogD: 1.25 |
Aromatic Rings: 4 | Heavy Atoms: 31 | QED Weighted: 0.46 | Np Likeness Score: -1.21 |
1. Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber ES, Balitza AE, Hartman GD, Coll KE, Rickert K, Shipman J, Shi B, Sepp-Lorenzino L, Thomas KA.. (2004) Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR., 14 (4): [PMID:15012992] [10.1016/j.bmcl.2003.12.007] |
Source(1):